The Lung Cancer Drug That Cut Death Risk in Half

An ADC With a Specific Target

Tam-Peli belongs to a class of drugs called antibody-drug conjugates, or ADCs. Think of them as guided missiles: an antibody finds a specific protein on the surface of cancer cells, latches on, and delivers a toxic payload directly inside. The idea is to kill the cancer while sparing healthy tissue, like sending a sniper instead of carpet-bombing.

Tam-Peli's target is a protein called B7-H3, which is overexpressed on many solid tumors, including SCLC. The payload it carries is a topoisomerase I inhibitor (a type of chemo agent), which gets released once the drug is inside the cancer cell.

What makes the safety data encouraging is that Tam-Peli actually caused fewer severe side effects than topotecan. That's unusual for a drug this potent. Most cancer breakthroughs come with a toxicity trade-off; this one appears to offer more efficacy and better tolerability.

Roche's $570 Million Bet Is Looking Smart

Back in January 2026, Roche inked an exclusive licensing deal with MediLink for Tam-Peli (known internally as YL201). Roche got worldwide rights outside of mainland China, Hong Kong, and Macau. The price tag: $570 million in upfront and near-term milestone payments, plus additional milestones and tiered royalties on future sales.

This wasn't Roche's first dance with MediLink, either. The two companies had already partnered in January 2024 on a different ADC called YL211, which targets c-Met. The Tam-Peli deal built on that existing relationship.

With the Phase 3 data now in hand, Roche is reportedly planning to launch global Phase 3 trials across multiple solid tumor types. The drug already has FDA Breakthrough Therapy Designation for SCLC, plus Orphan Drug Designations for SCLC, nasopharyngeal carcinoma, and esophageal squamous cell carcinoma. Meanwhile, MediLink's NDA (new drug application) was accepted by China's NMPA on September 2, 2026. The regulatory wheels are already turning.

The China Question

There's a wrinkle worth discussing. TAISHAN-302 was a China-only trial. That matters because the FDA has historically been cautious about approving drugs based solely on data from a single country, particularly when treatment patterns, patient demographics, and standard-of-care practices differ from those in the U.S.

The FDA's official position is that foreign data can support approval if they're applicable to the American population and conducted by competent investigators. In practice, though, single-country China trials have faced scrutiny. An FDA advisory committee previously questioned whether mainland China data alone were generalizable enough for U.S. approval in the checkpoint inhibitor space.

The EMA has shown somewhat more openness but still evaluates these submissions on a case-by-case basis. Most successful China-to-global approvals have relied on multiregional trials or pharmacokinetic bridging studies to demonstrate that results translate across populations.

This is precisely why Roche's involvement matters. The pharma giant has the infrastructure, regulatory expertise, and resources to run the global confirmatory trials that FDA will likely want to see. China generated the proof of concept; Roche can generate the global proof of generalizability.

A Crowded Race With High Stakes

Tam-Peli isn't alone in the SCLC ADC arena. Ifinatamab deruxtecan (I-DXd), a B7-H3 ADC from Daiichi Sankyo and Merck, is also in Phase 3 for SCLC, with a regulatory decision potentially coming in late 2026. That makes B7-H3 one of the hottest targets in lung cancer right now.

Beyond B7-H3, there are DLL3-targeted ADCs like zocilurtatug pelitecan in Phase 3, plus IDEAYA's IDE849 program reporting early response rates around 60% and moving toward registrational studies. AbbVie has a SEZ6-targeted ADC in development, too. The SCLC treatment landscape, long a graveyard of failed drugs, is suddenly buzzing with activity.

And then there's tarlatamab, a bispecific T-cell engager (not an ADC) that has already emerged as a preferred second-line option in many settings based on improved survival over standard-of-care chemotherapy. Tam-Peli will eventually need to prove itself against this newer standard, not just the aging topotecan comparator.

Why This Matters Beyond the Numbers

For patients with relapsed SCLC, the current reality is grim. You progress on platinum chemo, and your options have historically been limited to drugs with low response rates and short survival benefits. Tam-Peli's data suggest that a meaningful chunk of patients could see real, durable tumor shrinkage.

For the industry, this trial reinforces two big trends. First, ADCs are becoming the dominant innovation platform in oncology, with new targets and payloads producing results that old-school chemo simply can't match. Second, China-originated clinical data are increasingly driving global development decisions, even if regulatory acceptance remains a multi-step process.

Roche didn't spend $570 million on a hunch. They spent it on a drug that just posted one of the largest survival benefits ever seen in relapsed SCLC. Now the question is whether the rest of the world's regulators agree that these results are real enough to change practice everywhere, not just in China.